CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 237-243

  Tabarkiewicz, Jacek ^a   Rybojad, Pawel ^a   Jablonka, Andrzej ^a   Rolinski, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

BDCA; Blood dendritic cells antigen; Dendritic cells; Non small cell lung cancer

Indexed keywords

CD123 ANTIGEN; CD19 ANTIGEN; CD1C ANTIGEN; CD303 ANTIGEN; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER INFILTRATION; CANCER STAGING; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE; LYMPHOID CELL; MALE; MONONUCLEAR CELL; PLASMA CELL; PRIORITY JOURNAL;

EID: 38749092612     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.237     Document Type: Article

References (47)

1. Coppola D, Fu L, Nicosia SV, Kounelis S and Jones M: Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma. Hum Pathol 29: 455-462, 1998.
2. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN and Lotze MT: Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 124: 641-646, 1998.
3. Tsuge T, Yamakawa M and Tsukamoto M: Infiltrating dendritic/Langerhans cells in primary breast cancer. Breast Cancer Res Treat 59: 141-152, 2000.
4. Tsujitani S, Kakeji Y, Maehara Y, Sugimachi K and Kaibara N: Dendritic cells prevent lymph node metastasis in patients with gastric cancer. In Vivo 7: 233-237, 1993.
5. Zeid NA and Muller HK: S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25: 338-343, 1993.
6. Mailliard RB, Dallal RM, Son YI and Lotze MT: Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen. Immunol Invest 29: 177-185, 2000.
7. Chapoval AI, Tamada K and Chen L: In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 95: 2346-2351, 2000.
8. Shimamura H, Cumberland R, Hiroishi K, Watkins SC, Lotze MT and Baar J: Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. J Immunother 25: 226-234, 2002.
9. Vanderheyde N, Aksoy E, Amraoui Z, Vandenabeele P, Goldman M and Willems F: Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. J Immunol 167: 3565-3569, 2001.
10. Chaux P, Favre N, Bonnotte B, Moutet M, Martin M and Martin F: Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. Adv Exp Med Biol 417: 525-528, 1997.
11. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D and Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3: 483-490, 1997.
12. Nestle FO, Burg G, Fah J, Wrone-Smith T and Nickoloff BJ: Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 150: 641-651, 1997.
13. Pirtskhalaishvili G, Shurin GV, Esche C, et al: Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 83: 506-513, 2000.
14. Pirtskhalaishvili G, Shurin GV, Gambotto A, et al: Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol 165: 1956-1964, 2000.
15. Qin Z, Noffz G, Mohaupt M and Blankenstein T: Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 159: 770-776, 1997.
16. Vicari AP, Caux C and Trinchieri G: Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12: 33-42, 2002.
17. Almand B, Clark JI, Nikitina E, et al: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678-689, 2001.
18. Lissoni P, Brivio F, Ferrante R, et al: Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer. Int J Biol Markers 15: 22-25, 2000.
19. Wojas K, Tabarkiewicz J and Rolinski J: Dendritic cells in cancer patients. Folia Histochem Cytobiol 42: 45-48, 2004.
20. Enk AH, Jonuleit H, Saloga J and Knop J: Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73: 309-316, 1997.
21. Esche C, Lokshin A, Shurin GV, et al: Tumor's other immune targets: dendritic cells. J Leukoc Biol 66: 336-344, 1999.
22. Fanger NA, Maliszewski CR, Schooley K and Griffith TS: Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190: 1155-1164, 1999.
23. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP and Gabrilovich DI: Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 163: 3260-3268, 1999.
24. Shurin M and Gabrilovich D: Regulation of dendritic cell system by tumor. Cancer Res Ther Control 11: 65-78, 2001.
25. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT and Barksdale EM Jr: Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61: 363-369, 2001.
26. Hill G, Millar W and Connelly J: 'The great debate' 1: Smoking, lung cancer, and cancer epidemiology. Can Bull Med Hist 20: 367-386, 2003.
27. Radzikowska E, Glaz P and Roszkowski K: Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases. Ann Oncol 13: 1087-1093, 2002.
28. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J and Yannelli J: Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 22: 2808-2815, 2004.
29. Ishikawa A, Motohashi S, Ishikawa E, et al: A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910-1917, 2005.
30. Iwashita Y, Tahara K, Goto S. et al: A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 52: 155-161, 2003.
31. Dzionek A, Fuchs A, Schmidt P, et al: BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165: 6037-6046, 2000.
32. Dallal RM, Christakos P, Lee K, Egawa S, Son YI and Lotze MT: Paucity of dendritic cells in pancreatic cancer. Surgery 131: 135-138, 2002.
33. Bell D, Chomarat P, Broyles D, Netto G, et al: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190: 1417-1426, 1999.
34. Aalamian M, Pirtskhalaishvili G, Nunez A, et al: Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46: 68-75, 2001.
35. Makarenkova VP, Shurin GV, Tourkova IL, et al: Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J Neuroimmunol 145: 55-67, 2003.
36. Redlinger Jr RE, Mailliard RB and Barksdale Jr EM: Neuroblastoma and dendritic cell function. Semin Pediatr Surg 13: 61-71, 2004.
37. Bonfanti A, Lissoni P, Bucovec R, Rovelli F, Brivio F and Fumagalli L: Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer. Int J Biol Markers 15: 161-164, 2000.
38. Lissoni P, Malugani F, Bonfanti A, et al: Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 15: 140-144, 2001.
39. Shurin MR, Yurkovetsky ZR, Tourkova IL, Balkir L and Shurin GV: Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 101: 61-68, 2002.
40. Gabrilovich DI, Ciernik IF and Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170: 101-110, 1996.
41. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y and Sugimachi K: Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66: 2012-2016 1990.
42. Demedts IK, Brusselle GG, Vermaelen KY and Pauwels RA: Identification and characterization of human pulmonary dendritic cells. Am J Respir Cell Mol Biol 32: 177-184, 2005.
43. Demedts IK, Bracke KR, Maes T, Joos GF and Brusselle GG: Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am J Respir Cell Mol Biol 35: 387-393, 2006.
44. Almand B, Resser JR, Lindman B, et al: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766, 2000.
45. Aalamian M, Tourkova IL, Chatta GS, et al: Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol 170: 2026-2030, 2003.
46. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL and Furuya N: Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 55: 151-159, 2006.
47. Hoffmann TK, Muller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ and Whiteside TL: Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8: 1787-1793, 2002.